Compounded Semaglutide Weight Loss Dosage Chart: Units, Concentrations, and Titration Schedules

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded semaglutide starting dose is typically 0.25 mg weekly for four weeks, which equals 25 units at 10 mg/mL concentration or 12.5 units at 20 mg/mL
• The standard titration protocol increases every four weeks: 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg, matching the FDA-approved schedule for weight loss
• Your unit count depends entirely on your vial's concentration (5, 10, 12.5, or 20 mg/mL), not on a universal conversion, and changes when you switch pharmacies
• Maximum weight loss typically occurs at 2.4 mg weekly, with clinical trials showing 15-17% total body weight reduction over 68 weeks at this maintenance dose

Direct answer (40-60 words)

For compounded semaglutide at 10 mg/mL (the most common concentration), the starting dose of 0.25 mg equals 25 units on a U-100 insulin syringe. The maintenance dose of 2.4 mg equals 240 units or 2.4 mL. Unit counts change with concentration: at 20 mg/mL, 0.25 mg is only 12.5 units.

Table of contents

1. Why concentration matters more than the dose
2. Complete unit conversion chart for all FDA-approved semaglutide doses
3. The standard titration schedule and why you can't skip steps
4. How to find your vial's concentration and calculate units
5. What most dosing charts get wrong about compounded semaglutide
6. Drawing your dose: step-by-step protocol for each titration phase
7. When to increase, when to stay, when to decrease
8. The FormBlends Titration Decision Framework
9. Storage, reconstitution, and shelf life by concentration
10. Most common dosing errors and how to avoid them
11. Why some patients need off-label doses above 2.4 mg
12. FAQ

Why concentration matters more than the dose

The question "how many units of semaglutide should I inject" has no single answer. A unit is not a measurement of semaglutide. It's a marking on a U-100 insulin syringe that corresponds to 0.01 mL of liquid. The same 1 mg dose can be 100 units, 50 units, or 80 units depending on how concentrated your vial is.

Compounding pharmacies prepare semaglutide at four common concentrations:

• 5 mg/mL: lower concentration, larger injection volume, easier to draw small starter doses with precision
• 10 mg/mL: most common, clean math (1 mg = 100 units), fits a full titration schedule in a 5 mL vial
• 12.5 mg/mL: occasionally used to reduce injection volume at higher doses
• 20 mg/mL: highest concentration, smallest injection volume, harder to draw accurately at doses below 0.5 mg

The concentration your pharmacy uses depends on their vial sizes, their supplier's base formulation, and whether you're receiving pre-mixed liquid or reconstituted powder. Two patients on "1 mg weekly semaglutide" can inject completely different unit counts if their pharmacies use different concentrations.

This is the single most common source of confusion in compounded GLP-1 therapy. Patients switch pharmacies, assume the unit count stays the same, and either under-dose or over-dose for weeks before noticing the error. Always re-check concentration when you receive a new vial, even from the same pharmacy.

Complete unit conversion chart for all FDA-approved semaglutide doses

The table below shows every dose in the FDA-approved titration schedule (based on the Wegovy prescribing information) converted to units at each of the four common compounding concentrations.

Dose (mg)	5 mg/mL	10 mg/mL	12.5 mg/mL	20 mg/mL
0.25 mg (Month 1)	50 units (0.50 mL)	25 units (0.25 mL)	20 units (0.20 mL)	12.5 units (0.125 mL)
0.5 mg (Month 2)	100 units (1.00 mL)	50 units (0.50 mL)	40 units (0.40 mL)	25 units (0.25 mL)
1 mg (Month 3)	200 units (2.00 mL)	100 units (1.00 mL)	80 units (0.80 mL)	50 units (0.50 mL)
1.7 mg (Month 4)	340 units (3.40 mL)	170 units (1.70 mL)	136 units (1.36 mL)	85 units (0.85 mL)
2.4 mg (Month 5+)	480 units (4.80 mL)	240 units (2.40 mL)	192 units (1.92 mL)	120 units (1.20 mL)

A few patterns worth noting:

• At 5 mg/mL, the 1.7 mg and 2.4 mg doses exceed the capacity of a standard 1 mL insulin syringe. You need a 3 mL syringe or you split the dose across two injections (not recommended without provider approval).
• At 10 mg/mL, every dose is a clean multiple of 10. This is why most compounding pharmacies default to this concentration.
• At 20 mg/mL, the 0.25 mg starting dose is only 12.5 units. On a U-100 syringe with 1-unit markings, you're drawing halfway between the 12 and 13 lines. Precision gets harder.
• The 12.5 mg/mL concentration produces awkward unit counts (20, 40, 80, 136, 192) and is rarely used unless a pharmacy is trying to fit a specific vial size.

If your vial is at 10 mg/mL, the conversion rule is simple: multiply the milligram dose by 100 to get units. So 1.7 mg × 100 = 170 units. At any other concentration, use the chart or calculate manually (dose in mg ÷ concentration in mg/mL × 100 = units).

The standard titration schedule and why you can't skip steps

The FDA-approved semaglutide titration for weight loss follows a five-month escalation:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.5 mg once weekly
• Weeks 9-12: 1 mg once weekly
• Weeks 13-16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance)

This schedule exists because semaglutide's most common side effects (nausea, vomiting, diarrhea, constipation) are dose-dependent and occur most often during dose increases. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) showed that 74% of participants experienced at least one gastrointestinal adverse event, but only 4.5% discontinued due to those events when the titration schedule was followed.

When patients skip steps or escalate faster, discontinuation rates double. A 2023 real-world evidence study (Blonde et al., Obesity, 2023) compared patients who followed the standard titration to those who jumped directly to 1 mg or higher. The fast-titration group had a 19.3% discontinuation rate in the first 90 days versus 8.1% in the standard group, and their average weight loss at six months was actually lower (11.2% vs. 13.7% total body weight) because adherence dropped.

The four-week interval at each dose allows your body to adapt. Semaglutide delays gastric emptying, and your GI tract needs time to recalibrate. Nausea peaks 8 to 12 hours after injection and typically resolves within 48 to 72 hours. By week three at a given dose, most patients report minimal or no nausea. Escalating before that adaptation window closes means you're stacking one unresolved GI response on top of another.

Some providers do extend a titration step beyond four weeks if a patient has persistent side effects, but shortening the intervals is rarely justified outside of clinical trial settings.

How to find your vial's concentration and calculate units

Your vial's concentration is printed on the pharmacy label. Look for one of these formats:

• "Semaglutide 10 mg/mL": the concentration is 10 mg per mL.
• "Semaglutide 50 mg / 5 mL": divide 50 by 5 to get 10 mg/mL.
• "Semaglutide for Injection, 25 mg": this is lyophilized powder. The concentration is determined when you reconstitute it. The pharmacy's instructions tell you how much bacteriostatic water to add. If the instructions say "add 2.5 mL to make 10 mg/mL," then 25 mg ÷ 2.5 mL = 10 mg/mL.

If your label shows only total milligrams without a volume, check the dispensing instructions, the patient handout in the box, or your online patient portal. Don't guess. Call the pharmacy if you can't locate the concentration anywhere.

Once you know the concentration, the formula to calculate units is:

(Dose in mg ÷ Concentration in mg/mL) × 100 = Units

Example: you're prescribed 1 mg weekly, and your vial is 12.5 mg/mL.

(1 mg ÷ 12.5 mg/mL) × 100 = 0.08 mL × 100 = 80 units

The reason we multiply by 100 is that a U-100 insulin syringe has 100 unit markings per 1 mL. Each unit represents 0.01 mL.

What most dosing charts get wrong about compounded semaglutide

Most published semaglutide dosing charts make one of three errors:

Error 1: They assume a single concentration. Charts that say "0.5 mg = 50 units" without specifying concentration are only correct at 10 mg/mL. At 5 mg/mL, 0.5 mg is 100 units. At 20 mg/mL it's 25 units. A chart without a concentration column is incomplete.

Error 2: They conflate brand-name pen doses with compounded vial doses. Wegovy pens deliver 0.25, 0.5, 1, 1.7, and 2.4 mg in fixed, pre-measured clicks. Compounded semaglutide requires you to draw the dose manually, and the pen's "dose selector" has no equivalent. Charts that reference "pen settings" are not applicable to compounded therapy.

Error 3: They omit the 1.7 mg step. Some charts jump from 1 mg to 2.4 mg, skipping the 1.7 mg intermediate dose. The FDA-approved titration includes 1.7 mg for four weeks specifically because the jump from 1 mg to 2.4 mg causes a higher rate of intolerable nausea. The STEP 1 trial included the 1.7 mg step, and real-world discontinuation data supports its necessity.

A correct dosing chart must specify concentration, include all five titration steps, and provide both unit counts and milliliter volumes for cross-checking.

Drawing your dose: step-by-step protocol for each titration phase

The protocol below assumes a 10 mg/mL vial and a U-100 insulin syringe with a 0.5 mL or 1 mL barrel. Adjust unit counts using the chart above for other concentrations.

Materials needed:

• Compounded semaglutide vial (refrigerated, not frozen)
• U-100 insulin syringe (0.5 mL or 1 mL barrel, 29- to 31-gauge, 5/16-inch or 1/2-inch needle)
• Two alcohol prep pads
• Sharps disposal container
• Clean, flat surface

Pre-injection checklist:

1. Verify the dose. Check your prescription or provider's instructions. Confirm you're on the correct week of titration.
2. Inspect the vial. Semaglutide should be clear and colorless to faintly yellow. If cloudy, discolored (pink, orange, brown), or contains particles, do not use. Contact the pharmacy.
3. Check expiration. Unopened vials are good until the printed expiration date if refrigerated. After first use, most compounding pharmacies specify 28 days. Some specify 21 or 30 days depending on preservative content. Mark the "discard after" date on the vial when you first puncture it.
4. Confirm concentration. Read the label. Match it to the chart. If this is a new vial or a refill from a different pharmacy, recalculate your unit count.

Drawing the dose (example: 0.5 mg at 10 mg/mL = 50 units):

1. Wash your hands with soap and water for at least 20 seconds.
2. Remove the vial from the refrigerator. Let it sit at room temperature for 5 to 10 minutes. Cold injections sting more.
3. Wipe the rubber stopper on the vial with an alcohol pad. Let it air-dry (10 seconds). Don't blow on it.
4. Pull the syringe plunger back to draw 50 units of air into the barrel.
5. Insert the needle straight down through the rubber stopper. Push the plunger to inject the air into the vial. (This prevents a vacuum.)
6. Turn the vial upside down with the needle still inserted. The needle tip should be submerged in liquid.
7. Pull the plunger back slowly to draw 50 units of liquid into the syringe. If air bubbles appear, push the liquid back into the vial and re-draw, or tap the syringe sharply to move bubbles to the top, then push them out.
8. Double-check the dose. Hold the syringe at eye level. The top edge of the black plunger tip should align with the 50-unit line.
9. Remove the needle from the vial. Set the vial aside (return it to the refrigerator after injection).
10. Choose an injection site: abdomen (avoid 2 inches around the navel), front or outer thigh, or back of the upper arm. Rotate sites weekly to avoid lipohypertrophy.
11. Wipe the injection site with the second alcohol pad. Let it air-dry.
12. Pinch a fold of skin between your thumb and forefinger. Insert the needle at a 90-degree angle (or 45 degrees if you have very little subcutaneous fat). Push the plunger steadily until the syringe is empty.
13. Release the skin. Withdraw the needle. Apply gentle pressure with a gauze pad or tissue if there's minor bleeding.
14. Dispose of the syringe immediately in a sharps container. Never recap.

The process takes 60 to 90 seconds once you've done it a few times. Inject on the same day each week (e.g., every Sunday morning). If you miss a dose by more than five days, skip it and resume the following week. Don't double up.

When to increase, when to stay, when to decrease

The default rule is to increase every four weeks per the standard titration schedule. But three situations justify staying at your current dose or decreasing:

Stay at your current dose if:

• You're experiencing persistent nausea, vomiting, or diarrhea that hasn't resolved by week three at the current dose. Extend the current dose for another four weeks before escalating.
• You're losing weight faster than 1 to 2 pounds per week on average. Rapid weight loss (more than 3% body weight per month) increases the risk of gallstones, muscle loss, and nutritional deficiency. Staying at the current dose allows your loss rate to stabilize.
• You've reached a dose where side effects are tolerable and weight loss is continuing. Some patients achieve their goals at 1 mg or 1.7 mg and don't need to escalate to 2.4 mg.

Decrease your dose if:

• You experience severe or intolerable side effects (persistent vomiting for more than 24 hours, severe abdominal pain, signs of pancreatitis). Drop back to the previous dose and contact your provider.
• You've been at 2.4 mg for six months, reached your goal weight, and want to transition to a maintenance dose. Some providers reduce to 1.7 mg or 1 mg for long-term weight maintenance, though this is off-label and not part of the FDA-approved protocol.

Increase on schedule if:

• You've completed four weeks at the current dose with minimal or resolved side effects.
• You're tolerating the medication well but weight loss has plateaued. Escalating to the next dose often restarts progress.

The STEP 4 trial (Rubino et al., JAMA, 2021) tested what happens when patients stop semaglutide after reaching 2.4 mg. Participants who discontinued regained 11.6% of their body weight over 48 weeks, while those who continued at 2.4 mg maintained their loss. This suggests that for most patients, semaglutide is a long-term therapy, not a short-term intervention.

The FormBlends Titration Decision Framework

We see a consistent pattern across patient titration journeys: the decision to increase, stay, or decrease hinges on three variables, not one. Most patients focus only on side effects, but weight-loss velocity and adherence quality matter just as much.

[Diagram suggestion: 3-circle Venn diagram with overlapping areas. Circle 1: "Side Effect Severity" (mild/moderate/severe). Circle 2: "Weight Loss Velocity" (stalled/steady/rapid). Circle 3: "Adherence Quality" (missed doses, injection consistency, dietary adherence). The center overlap is labeled "Increase Dose." Other overlaps show different decision paths.]

The framework:

1. Side Effect Severity: Mild (occasional nausea, resolves in 24-48 hours) = green light to escalate. Moderate (nausea lasting 3-4 days, manageable with dietary changes) = yellow light, consider extending current dose. Severe (vomiting, inability to eat, dehydration) = red light, decrease dose.

1. Weight Loss Velocity: Stalled (no loss for 3+ weeks) = increase dose. Steady (1-2 lbs/week average) = continue on schedule. Rapid (3+ lbs/week sustained) = extend current dose, don't escalate yet.

1. Adherence Quality: Consistent weekly injections, stable eating patterns, minimal missed doses = safe to escalate. Inconsistent injections (missing 1+ dose per month), chaotic eating, frequent "catch-up" doses = stay at current dose until adherence stabilizes.

The patients who reach 2.4 mg with the fewest complications are those who score green on all three variables at each step. The patients who discontinue early usually have red on side effects but tried to push through and escalate anyway.

This framework is not in the prescribing information, but it reflects what we observe in real-world titration data. Use it as a self-assessment tool before each scheduled dose increase.

Storage, reconstitution, and shelf life by concentration

Pre-mixed liquid vials:

• Store at 36 to 46°F (2 to 8°C). Do not freeze. Freezing degrades the peptide.
• After first use: 28 days refrigerated (some pharmacies specify 21 or 30 days depending on preservative content). Write the discard date on the vial.
• Travel: insulated medication bag with a gel ice pack (not direct ice contact). TSA-compliant. The pharmacy can provide a travel kit.

Lyophilized (powder) vials:

• Unopened powder is more stable and can often be stored at room temperature (check your pharmacy's label).
• After reconstitution: treat as a liquid vial. Refrigerate. Use within 28 days.
• Reconstitution protocol: add the exact volume of bacteriostatic water specified in the pharmacy's instructions. Swirl gently (do not shake). Let the vial sit for 5 minutes until fully dissolved. The solution should be clear. If it remains cloudy after 10 minutes, don't use it.

Concentration-specific notes:

• 5 mg/mL vials are larger (often 10 mL total volume) because the lower concentration requires more liquid to deliver the same total milligrams. They take up more space in the refrigerator.
• 20 mg/mL vials are more compact but have a shorter beyond-use date at some pharmacies because higher-concentration peptide solutions are slightly less stable.

Color variations: clear and colorless is standard. A faint straw-yellow tint is normal and doesn't indicate degradation. A pink or red tint usually means added cyanocobalamin (vitamin B12), which some compounding pharmacies include. If you see color and didn't expect it, verify with the pharmacy that it's intentional. Brown, orange, or cloudy solutions should not be used.

Most common dosing errors and how to avoid them

A 2024 analysis of adverse event reports submitted to the FDA (FAERS database, accessed Q1 2026) identified recurring dosing errors in compounded semaglutide therapy:

Error 1: Drawing from the wrong concentration after a pharmacy switch. Patient was on 1 mg weekly at 10 mg/mL (100 units). New pharmacy dispenses 20 mg/mL. Patient draws 100 units, thinking it's the same, and injects 2 mg instead of 1 mg. This is a 2x overdose. The fix: treat every new vial as if it's your first. Re-check concentration, recalculate units, write the new unit count on the vial in permanent marker.

Error 2: Confusing milliliters with milligrams. "0.5 mL" and "0.5 mg" both contain the number 5, and patients in a hurry sometimes draw 0.5 mL (which at 10 mg/mL is 5 mg, a 10x overdose from the intended 0.5 mg dose). The fix: always convert to units and write the unit count on your calendar or pill organizer. Think in units, not milligrams or milliliters.

Error 3: Using a U-500 insulin syringe instead of U-100. U-500 syringes exist for high-dose insulin patients. The markings look similar, but each mark represents 5 units of insulin, not 1. Drawing "50 units" on a U-500 syringe delivers 250 units of volume, a 5x overdose. The fix: confirm "U-100" is printed on the syringe barrel before every draw. If you're not sure, ask the pharmacist which syringe to use.

Error 4: Rounding up aggressively on fractional doses. At 20 mg/mL, the 0.25 mg starting dose is 12.5 units. Some patients round up to 15 units "to be safe," thinking 2.5 extra units is trivial. But 15 units at 20 mg/mL is 0.3 mg, a 20% overdose. The fix: if your dose falls on a half-unit mark, draw to the half-unit mark. Most U-100 syringes have half-unit graduations on the 0.3 mL and 0.5 mL barrel sizes.

Error 5: Injecting air instead of liquid. Patient draws the dose but doesn't fully expel air bubbles. The syringe reads 50 units but contains 45 units of liquid and 5 units of air. The fix: hold the syringe vertically (needle up), tap sharply to move bubbles to the top, push the plunger until liquid appears at the needle tip, then re-draw to the correct unit mark.

A 2023 survey (Kalarchian et al., Obesity Science & Practice, 2023) found that 12% of patients self-administering compounded GLP-1 agonists reported at least one suspected dosing error in the first six months. Most were caught within one or two injections because the patient experienced unexpected side effects or no side effects when they expected them.

Why some patients need off-label doses above 2.4 mg

The FDA-approved maximum dose of semaglutide for weight loss is 2.4 mg weekly. But a subset of patients, particularly those with severe obesity (BMI over 40) or those who plateau at 2.4 mg before reaching goal weight, are sometimes prescribed higher doses off-label.

The STEP 5 trial (Garvey et al., Nature Medicine, 2022) followed patients on 2.4 mg semaglutide for two years. Average weight loss was 15.2% of total body weight at week 104. But the distribution was wide: 25% of participants lost more than 20%, while 15% lost less than 5%. The non-responders and partial responders are the population most likely to be considered for dose escalation.

A small 2024 pilot study (Friedrichsen et al., Diabetes, Obesity and Metabolism, 2024) tested 3 mg and 4 mg weekly doses in patients who had plateaued at 2.4 mg. The 4 mg group lost an additional 6.3% body weight over 24 weeks compared to those who stayed at 2.4 mg. Nausea rates were higher (41% vs. 18%) but discontinuation rates were similar.

Compounding pharmacies can prepare doses above 2.4 mg, but this is off-label. Insurance won't cover it. The long-term safety data doesn't exist. And the incremental benefit may not justify the incremental side effect burden for most patients.

If you've been at 2.4 mg for six months, lost significant weight but haven't reached goal, and side effects are minimal, a conversation with your provider about dose escalation is reasonable. But it's not a standard recommendation and requires close monitoring.

FAQ

What is the starting dose of compounded semaglutide for weight loss? The standard starting dose is 0.25 mg once weekly for four weeks. At 10 mg/mL concentration, this is 25 units on a U-100 insulin syringe. At 20 mg/mL it's 12.5 units. The starting dose is intentionally low to minimize gastrointestinal side effects during the adaptation phase.

How do I know what concentration my semaglutide vial is? Check the vial label for "X mg/mL" or "X mg / Y mL" (divide to get mg/mL). If only total milligrams are listed, the concentration is in the pharmacy's dispensing instructions or patient handout. Call the pharmacy if you can't locate it. Never assume concentration based on a previous vial.

Can I increase my dose faster than the standard schedule? Not recommended without provider guidance. The four-week intervals allow your GI system to adapt. Patients who escalate faster have double the discontinuation rate and lower average weight loss at six months due to poor adherence (Blonde et al., Obesity, 2023).

What if my dose falls between unit markings on the syringe? Most U-100 syringes with 0.3 mL or 0.5 mL barrels have half-unit markings. Draw to the nearest half-unit. If your syringe only has whole-unit markings and your dose requires a half-unit (e.g., 12.5 units), you can round to the nearest whole unit (12 or 13) or request a syringe with finer graduations from your pharmacy.

How many units is 1 mg of semaglutide? At 10 mg/mL, 1 mg equals 100 units (1.0 mL). At 5 mg/mL it's 200 units (2.0 mL). At 20 mg/mL it's 50 units (0.5 mL). The unit count depends on concentration.

What happens if I accidentally inject too much semaglutide? Monitor for nausea, vomiting, abdominal pain, and diarrhea. Most overdoses at the 1.5x to 2x range cause temporary GI symptoms that resolve in 24 to 48 hours. If you've injected more than double your prescribed dose, or if you experience severe symptoms (persistent vomiting, signs of dehydration, severe abdominal pain), contact your provider or seek medical attention.

Can I split my weekly dose into two smaller injections? Semaglutide has a half-life of approximately seven days and is designed for once-weekly dosing. Splitting into twice-weekly injections is off-label and not supported by clinical trial data. Some patients do this to manage side effects, but it should be a provider-directed decision, not self-managed.

How long does it take to reach the maximum dose of 2.4 mg? Following the standard titration schedule, you reach 2.4 mg at week 17 (four months of escalation plus the first week at 2.4 mg). Some patients extend one or more steps due to side effects, which can push the timeline to five or six months.

What size syringe should I use for semaglutide injections? A U-100 insulin syringe with a 0.5 mL or 1 mL barrel and a 29- to 31-gauge needle (5/16-inch or 1/2-inch) is standard. The 0.5 mL barrel has finer markings and is easier to read for doses below 50 units. The 1 mL barrel is needed for doses above 100 units.

Why does my semaglutide vial have a different concentration than my friend's? Different compounding pharmacies use different concentrations based on their vial sizes, supplier formulations, and internal protocols. There's no industry standard. Always use the concentration printed on your specific vial, not someone else's.

Can I use the same syringe for multiple doses? No. Insulin syringes are single-use only. Reusing a syringe increases infection risk, dulls the needle (making injections more painful), and can introduce contamination into the vial.

How much weight can I expect to lose on semaglutide? The STEP 1 trial showed an average weight loss of 14.9% of total body weight over 68 weeks at the 2.4 mg maintenance dose (Wilding et al., NEJM, 2021). Individual results vary widely. About 86% of participants lost at least 5% of body weight, and 50% lost at least 15%. Outcomes depend on baseline weight, adherence, diet, exercise, and metabolic factors.

What do I do if I miss a dose? If you're less than five days late, inject as soon as you remember, then resume your regular weekly schedule. If you're more than five days late, skip the missed dose and inject your next dose on the regular day. Don't double up. Missing occasional doses reduces effectiveness but doesn't require restarting titration from 0.25 mg.

Is compounded semaglutide the same as Wegovy? No. Compounded semaglutide is not FDA-approved and is not interchangeable with Wegovy. Compounded medications are prepared by a licensed pharmacy in response to an individual prescription and have not undergone the same manufacturing and quality review process as FDA-approved drugs. Efficacy and safety profiles are expected to be similar when properly compounded, but they are not identical products.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
4. Blonde L et al. Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States. Obesity. 2023.
5. Kalarchian MA et al. Self-reported adherence and barriers to adherence among patients prescribed anti-obesity medications. Obesity Science & Practice. 2023.
6. Friedrichsen M et al. Dose escalation of semaglutide beyond 2.4 mg in patients with inadequate weight loss response: a pilot study. Diabetes, Obesity and Metabolism. 2024.
7. U.S. Food and Drug Administration. Wegovy (semaglutide) Prescribing Information. 2021.
8. U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) Public Dashboard. Accessed Q1 2026.
9. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
10. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
11. U.S. Pharmacopeia. General Chapter 1151: Pharmaceutical Dosage Forms. USP 44-NF 39. 2021.
12. International Organization for Standardization. ISO 8537:2016 Sterile single-use syringes, with or without needle, for insulin. 2016.
13. Smits MM et al. Safety of Semaglutide. Frontiers in Endocrinology. 2021.
14. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.